SK1872001A3 - Hydroxy pipecolate hydroxamic acid derivatives and pharmaceutical compositions containing them - Google Patents

Hydroxy pipecolate hydroxamic acid derivatives and pharmaceutical compositions containing them Download PDF

Info

Publication number: SK1872001A3
Authority: SK; Slovakia
Prior art keywords: alkyl; carbon atoms; hydroxy; carboxylic acid; pharmaceutically acceptable
Prior art date: 1998-08-12

Application number

SK187-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Kim Francis Mcclure

Mark Carl Noe

Michael Anthony Letavic

Louis Stanley Chupak

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-12

Filing date

1999-08-05

Publication date

2002-08-06

1999-08-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-08-06 Publication of SK1872001A3 publication Critical patent/SK1872001A3/sk

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

SK187-2001A 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives and pharmaceutical compositions containing them SK1872001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9623298P	1998-08-12	1998-08-12
PCT/IB1999/001388 WO2000009485A1 (en)	1998-08-12	1999-08-05	Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors

Publications (1)

Publication Number	Publication Date
SK1872001A3 true SK1872001A3 (en)	2002-08-06

Family

ID=22256467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK187-2001A SK1872001A3 (en)	1998-08-12	1999-08-05	Hydroxy pipecolate hydroxamic acid derivatives and pharmaceutical compositions containing them

Country Status (43)

Country	Link
US (2)	US6329397B1 (uk)
EP (1)	EP1104403B1 (uk)
JP (1)	JP2002522528A (uk)
KR (1)	KR20010085374A (uk)
CN (1)	CN1316995A (uk)
AP (1)	AP2001002070A0 (uk)
AR (1)	AR019241A1 (uk)
AT (1)	ATE325791T1 (uk)
AU (1)	AU766366B2 (uk)
BG (1)	BG105323A (uk)
BR (1)	BR9912909A (uk)
CA (1)	CA2340202C (uk)
CZ (1)	CZ2001484A3 (uk)
DE (1)	DE69931266T2 (uk)
DZ (1)	DZ2870A1 (uk)
EA (1)	EA200100126A1 (uk)
EE (1)	EE200100086A (uk)
ES (1)	ES2263279T3 (uk)
GE (1)	GEP20033117B (uk)
GT (1)	GT199900131A (uk)
HK (1)	HK1040242A1 (uk)
HN (1)	HN1999000131A (uk)
HR (1)	HRP20010098A2 (uk)
HU (1)	HUP0103452A3 (uk)
ID (1)	ID27840A (uk)
IL (1)	IL141030A0 (uk)
IS (1)	IS5813A (uk)
MA (1)	MA26675A1 (uk)
NO (1)	NO20010686L (uk)
NZ (1)	NZ509296A (uk)
OA (1)	OA11594A (uk)
PA (1)	PA8479201A1 (uk)
PE (1)	PE20000951A1 (uk)
PL (1)	PL346041A1 (uk)
SK (1)	SK1872001A3 (uk)
SV (1)	SV1999000123A (uk)
TN (1)	TNSN99156A1 (uk)
TR (1)	TR200100474T2 (uk)
UA (1)	UA59453C2 (uk)
UY (1)	UY25993A1 (uk)
WO (1)	WO2000009485A1 (uk)
YU (1)	YU5201A (uk)
ZA (1)	ZA200101042B (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en)	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6531488B1 (en) *	1998-08-31	2003-03-11	Merck & Co., Inc.	Method of treating neurodegenerative diseases
US6509337B1 (en) *	1998-09-17	2003-01-21	Pfizer Inc.	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (en) *	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
EP1138680A1 (en) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) *	2000-09-27	2002-04-10	Shionogi & Co Ltd	新規マトリックスメタロプロテアーゼ阻害剤
EP1368323B1 (en)	2001-02-14	2010-06-30	Warner-Lambert Company LLC	Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
CA2462442A1 (en)	2001-10-12	2003-04-24	Warner-Lambert Company Llc	Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
KR20050013616A (ko) *	2002-06-26	2005-02-04	카나 바이오사이언스 인코포레이션	신규 아자당 유도체 및 이것을 유효성분으로 하는 약제
EP1525030A1 (en) *	2002-07-17	2005-04-27	Warner-Lambert Company LLC	Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
MXPA05000476A (es) *	2002-07-17	2005-03-23	Warner Lambert Co	Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib.
CA2497658A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006500351A (ja)	2002-08-13	2006-01-05	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
AU2003249540A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
WO2004014923A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014908A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
BR0313459A (pt)	2002-08-13	2005-06-21	Warner Lambert Co	Derivados monocìclicos como inibidores de metaloproteinases de matriz
AU2003249531A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
WO2006131836A2 (en) *	2005-03-22	2006-12-14	Innodia Inc.	Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
ATE494926T1 (de)	2008-03-25	2011-01-15	Affectis Pharmaceuticals Ag	Neuartige p2x7r-antagonisten und ihre verwendung
MX2011010810A (es)	2009-04-14	2012-01-12	Affectis Pharmaceuticals Ag	Nuevos antagonistas de p2x7r y su uso.
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
DE202016007195U1 (de)	2016-11-16	2017-11-17	Bernhard Kohler	Strombegrenzende Schalteinrichtung
WO2020160140A1 (en) *	2019-01-29	2020-08-06	Darsha Llc	Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0821671T3 (da) *	1995-04-20	2001-04-23	Pfizer	Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US6153757A (en) *	1995-12-08	2000-11-28	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors and intermediates useful for their preparation
WO1998008815A1 (en) *	1996-08-28	1998-03-05	The Procter & Gamble Company	Substituted cyclic amine metalloprotease inhibitors
PT977733E (pt) *	1997-02-03	2003-12-31	Pfizer Prod Inc	Derivados de acido arilsulfonilamino-hidroxamico
BR9807678A (pt) *	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
WO1998050348A1 (en) *	1997-05-09	1998-11-12	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

1999
- 1999-05-08 UA UA2001010473A patent/UA59453C2/uk unknown
- 1999-07-30 PA PA19998479201A patent/PA8479201A1/es unknown
- 1999-08-03 YU YU5201A patent/YU5201A/sh unknown
- 1999-08-05 NZ NZ509296A patent/NZ509296A/en unknown
- 1999-08-05 KR KR1020017001847A patent/KR20010085374A/ko not_active Application Discontinuation
- 1999-08-05 ES ES99933076T patent/ES2263279T3/es not_active Expired - Lifetime
- 1999-08-05 AP APAP/P/2001/002070A patent/AP2001002070A0/en unknown
- 1999-08-05 AT AT99933076T patent/ATE325791T1/de not_active IP Right Cessation
- 1999-08-05 CA CA002340202A patent/CA2340202C/en not_active Expired - Fee Related
- 1999-08-05 PL PL99346041A patent/PL346041A1/xx not_active Application Discontinuation
- 1999-08-05 HU HU0103452A patent/HUP0103452A3/hu unknown
- 1999-08-05 OA OA1200100035A patent/OA11594A/en unknown
- 1999-08-05 IL IL14103099A patent/IL141030A0/xx unknown
- 1999-08-05 ID IDW20010327A patent/ID27840A/id unknown
- 1999-08-05 AU AU49247/99A patent/AU766366B2/en not_active Ceased
- 1999-08-05 WO PCT/IB1999/001388 patent/WO2000009485A1/en active IP Right Grant
- 1999-08-05 CN CN99810697A patent/CN1316995A/zh active Pending
- 1999-08-05 EP EP99933076A patent/EP1104403B1/en not_active Expired - Lifetime
- 1999-08-05 TR TR2001/00474T patent/TR200100474T2/xx unknown
- 1999-08-05 EE EEP200100086A patent/EE200100086A/xx unknown
- 1999-08-05 CZ CZ2001484A patent/CZ2001484A3/cs unknown
- 1999-08-05 SK SK187-2001A patent/SK1872001A3/sk unknown
- 1999-08-05 BR BR9912909-4A patent/BR9912909A/pt not_active Application Discontinuation
- 1999-08-05 DE DE69931266T patent/DE69931266T2/de not_active Expired - Fee Related
- 1999-08-05 GE GEAP19995744A patent/GEP20033117B/en unknown
- 1999-08-05 JP JP2000564939A patent/JP2002522528A/ja not_active Ceased
- 1999-08-05 EA EA200100126A patent/EA200100126A1/ru unknown
- 1999-08-09 HN HN1999000131A patent/HN1999000131A/es unknown
- 1999-08-10 AR ARP990103994A patent/AR019241A1/es not_active Application Discontinuation
- 1999-08-10 PE PE1999000807A patent/PE20000951A1/es not_active Application Discontinuation
- 1999-08-11 MA MA25730A patent/MA26675A1/fr unknown
- 1999-08-11 TN TNTNSN99156A patent/TNSN99156A1/fr unknown
- 1999-08-11 SV SV1999000123A patent/SV1999000123A/es not_active Application Discontinuation
- 1999-08-11 DZ DZ990170A patent/DZ2870A1/xx active
- 1999-08-12 US US09/372,946 patent/US6329397B1/en not_active Expired - Fee Related
- 1999-08-12 GT GT199900131A patent/GT199900131A/es unknown
2000
- 2000-01-28 UY UY25993A patent/UY25993A1/es unknown
2001
- 2001-01-16 IS IS5813A patent/IS5813A/is unknown
- 2001-02-07 ZA ZA200101042A patent/ZA200101042B/en unknown
- 2001-02-08 HR HR20010098A patent/HRP20010098A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010686A patent/NO20010686L/no not_active Application Discontinuation
- 2001-03-09 BG BG105323A patent/BG105323A/xx unknown
- 2001-12-03 US US10/008,943 patent/US20030008901A1/en not_active Abandoned
2002
- 2002-02-26 HK HK02101437.7A patent/HK1040242A1/zh unknown

Also Published As

Publication number	Publication date
AU4924799A (en)	2000-03-06
KR20010085374A (ko)	2001-09-07
DE69931266T2 (de)	2007-02-15
EP1104403A1 (en)	2001-06-06
AU766366B2 (en)	2003-10-16
PE20000951A1 (es)	2000-09-27
ZA200101042B (en)	2002-10-07
UY25993A1 (es)	2000-03-31
OA11594A (en)	2004-07-11
HN1999000131A (es)	2000-03-24
HK1040242A1 (zh)	2002-05-31
IL141030A0 (en)	2002-02-10
NO20010686L (no)	2001-04-09
SV1999000123A (es)	2000-07-06
DE69931266D1 (en)	2006-06-14
HRP20010098A2 (en)	2002-02-28
AR019241A1 (es)	2001-12-26
ATE325791T1 (de)	2006-06-15
HUP0103452A2 (hu)	2002-04-29
NZ509296A (en)	2003-10-31
DZ2870A1 (fr)	2003-12-15
IS5813A (is)	2001-01-16
CA2340202C (en)	2006-02-07
CZ2001484A3 (cs)	2002-05-15
PL346041A1 (en)	2002-01-14
PA8479201A1 (es)	2000-09-29
TR200100474T2 (tr)	2001-06-21
US6329397B1 (en)	2001-12-11
BG105323A (en)	2001-10-31
ES2263279T3 (es)	2006-12-01
EA200100126A1 (ru)	2001-08-27
CN1316995A (zh)	2001-10-10
YU5201A (sh)	2003-07-07
CA2340202A1 (en)	2000-02-24
EE200100086A (et)	2002-08-15
TNSN99156A1 (fr)	2005-11-10
UA59453C2 (uk)	2003-09-15
MA26675A1 (fr)	2004-12-20
GT199900131A (es)	2001-02-02
BR9912909A (pt)	2001-05-08
ID27840A (id)	2001-04-26
HUP0103452A3 (en)	2002-10-28
GEP20033117B (en)	2003-11-25
WO2000009485A1 (en)	2000-02-24
EP1104403B1 (en)	2006-05-10
JP2002522528A (ja)	2002-07-23
NO20010686D0 (no)	2001-02-09
US20030008901A1 (en)	2003-01-09
AP2001002070A0 (en)	2001-03-31

Publication	Publication Date	Title
SK1872001A3 (en)	2002-08-06	Hydroxy pipecolate hydroxamic acid derivatives and pharmaceutical compositions containing them
JP3188883B2 (ja)	2001-07-16	５−オキソ−ピロリジン−２−カルボン酸・ヒドロキシアミド誘導体
SK14892000A3 (sk)	2002-03-05	Hydroxamidy (4-sulfonylamino)tetrahydropyrán-4-karboxylových kyselín, farmaceutické kompozície a ich použitie
US6214870B1 (en)	2001-04-10	Dioxocyclopentyl hydroxamic acids
SK14902000A3 (sk)	2002-05-09	Bicyklické deriváty hydroxámovej kyseliny, ich použitie a farmaceutické kompozície na ich báze
JP3623448B2 (ja)	2005-02-23	Ｔａｃｅインヒビター
US6156798A (en)	2000-12-05	Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
MXPA01003247A (es)	2002-03-08	Acidos hidroxamicos sustituidos geminalmente.
JP2004168786A (ja)	2004-06-17	薬剤組成物
EP1134215B1 (en)	2004-10-06	2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases
US6387901B1 (en)	2002-05-14	Alkyne containing metalloproteinase inhibitors
JP3828748B2 (ja)	2006-10-04	３−（アリールスルホニルアミノ）−テトラヒドロフラン−３−カルボン酸ヒドロキシアミド
JP2003500485A (ja)	2003-01-07	３−（アリールスルホニルアミノ）−テトラヒドロピラン−３−カルボン酸ヒドロキシアミド
MXPA00003181A (en)	2001-12-04	Dioxocyclopentyl hydroxamic acids
MXPA01002603A (en)	2002-06-05	2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases
MXPA99010152A (en)	2000-05-01	Hydroxyamide derivatives of 5-oxo-pirrolidine-2-carboxyl acid